Almac Clinical Technologies announces IXRS®3 as market leading in key industry report

Almac Clinical Technologies announces IXRS®3 as market leading in key industry report

Almac Clinical Technologies (ACT), part of the Almac Group, has been ranked as the industry’s most preferred IRT application globally, among recent users in a recent independent survey for their Interactive Response Technology (IRT) software, IXRS®3.  61 per cent of ACT’s recent users chose ACT as the provider they most prefer to use.

Industry Standard Research (ISR)’s ‘IRT Market Dynamics and Service Provider Benchmarking report’, published in October 2022, is designed to help key decision makers across the eClinical ecosphere to stay current with market dynamics and anticipate industry changes. Feedback was assessed from over 100 respondents throughout the professional IRT community, and the results are categorized by IRT supplier performance and preference metrics.

Almac’s IXRS®3 solution was ranked first in the “IRT Vendor Preference” section out of over 20 global companies based on respondents’ experience with the platform. The customer feedback showcased ACT as a top performer in project manager quality, ease of use for the clinical and site teams, reporting and cross study-design functionality.

Used in over 4,000 clinical trials in over 120 countries, IXRS®3 is available to deploy through multiple start up modes and is the most configurable and customizable IRT available. From Phase I through to Phase IV, simple designs to complex adaptive trials, the application can accommodate any permutation of study objectives, and is fully supported by a team of eClinical professionals with supporting services in biostatistics, systems integrations and regulatory compliance.

Valarie Higgins, President and Managing Director, Almac Clinical Technologies said: “These survey results not only affirm Almac Clinical Technologies’ software as the global leader but the data also highlights the importance of the people and expertise behind the technology which is unique to Almac.

“I am proud of the customer service our teams provide for customers, supporting them throughout their IRT journey through a fully streamlined partnership.”

These results reflect the findings of a similar survey that was carried out earlier this year by a third-party provider on behalf of ACT.  The results also cement an industry leading position for ACT’s IXRS software on a range of key performance indicators.

ends

Notes to editor:

• ACT is the most popular IRT software provider amongst those with prior experience of a range of IRT companies, with 61% of respondents saying that ACT is the company they most prefer to use.
• The survey included 108 respondents from North America, Europe and Asia.

About Almac Group  

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture. 

The international company is a privately owned organisation which has grown organically over the past five decades now employing over 6,500 highly skilled personnel across 18 facilities including Europe, the USA and Asia. 

The figures quoted in this announcement relate to the financial period 1 October 2020 to 30 September 2021. Employee numbers recorded in the results relates to the average figures during that financial year. 

To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.